Musso G, Cassader M, Rosina F, et al
Below, find out more about how much they cost, whether they tend to be covered by insurance, and more
A clinician prescribing GLP-1 therapy to a 72-year-old Medicare beneficiary under the Bridge Program has no regulatory obligation to assess baseline muscle status or bone density, even though both are known to be adversely affected by rapid weight loss in older adults, and even though the new bone density signal from the July 2026 Journal of Clinical Endocrinology and Metabolism study adds to those concerns
However, some health insurance companies are starting to expand their coverage for GLP-1s
In some cases, authorized generics helped speed early availability, but broader competition still took time to develop